Citations

Clear

133 citation(s) found for "Church, An".

Advancing Prostate Cancer Survivorship Through Transatlantic Consortium Science: The iCCaRE Initiative
Odedina, Folakemi T. , Dronca, Roxana , Ashing, Kimlin , Kaninjing, Ernest , Rotimi, Solomon O. , Ngufor, Che , Merriweather, Arnold , Gordon, Vinessa , Asto-Flores, Emelina , Adeniji, Kayode, Agboola, Emmanuel, Aliche, Uju, Aliyu, Usman M., Ashing, Kimlin Tam, Asiedu, Gladys, Badejo, Paul, Johnson, Kim Barbel, Beckford, Patrick , Blocker, Renaldo, Bolajoko, Opeyemi, Bonner, Timethia J, Breland, Ivey, Caballero, Amanda , Carter, Rickey, Cattnell, Alex, COBRAN, Ewan, Colon-Otero, Gerardo, Copland, John A., Phd, Getachew Dagne, Campos, Opeyemi C. De, Doty, Melissa, Dronca, Roxana, Erefah, Ebenezer, Falzon, Kaila, Francis, Damian, Fudge, Michelle, Fullwood, Dottington , Gainer, Jeffery, Glaser-Boivin, Dee, Hill, Antony, Hinsom, Rakenya, Iweala, Emeka J., Kaninjing, Ernie, Kase, Adam, Knutsen, Keith, Lee, Daniel, Leyva, Sandra Casanova, Lindeman, Carolyn R., Mahin, Collisa, Maniaci, Michael, Hew, Trevanne Matthews, Hew, Trevanne R. Matthews, Melton, Jada K., Merriweather, Arnold, Mitchell, Luisa, Moore, Cassandra, Ngufor, Che, Nolan, Lucia, Odedina, Abimbola, Odedina, Folakemi, Oladoyinbo, Catherine, Olasehinde, Esther, Onyia, Abimbola F., Popoola, Ademoola, Rotimi, Solomon O., Scales, Tracie, Sledge, Hanna, Thompson-Reeves, Jade, Toye, Oluwaseyi, Duarte, Claudia Valles, Voorhis, Kaitlin Van, Waldon, Charles F., Walsh-Childers, Kim , Williams, Christopher, Willis, Floyd , Wimberly, Quincy , Yahaya, Ayinde, Yates, PhD Clayton, Yost, Kathleen, Young, Mary Ellen , Zou, Tingyu, Ashing, Kimlin Tam , Rotimi, Solomon , Odedina, Folakemi , Kaninjing, Ernest T , Ngufor, Che G , Aliche, Uju, Badejo, Paul, Blocker, Renaldo, Bolajoko, Opeyemi , Cattnell, Alex, Cobran, Ewan K. , Colon-Otero, Gerardo, Copland, John A., Francis, Damian, Fudge, Michelle , Gainer, Jeffery, Gokara, Mahesh , Hinsom, Rakenya, Iweala, Emeka J., Knutsen, Keith, Lee, Daniel, Lindeman, Carolyn R., McCall, John , Melton, Jada K., Mitchell, Luisa, Olasehinde, Esther, Popoola, Ademoola, Reynolds, Jordan , Scales, Tracie, Sledge, Hanna, Thompson-Reeves, Jade, Toye, Oluwaseyi, Duarte, Claudia Valles, Voorhis, Kaitlin Van, Waldon, Charles F., Williams, Christopher, Yost, Kathleen, Zou, Tingyu

Mayo Clinic

Cancer Research Communications | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0165 | PMID 42497456 Get It

Abstract Black/African American populations, globally, bear the greatest prostate cancer (CaP) burden compared to other racial/ethnic groups. Addressing CaP disparities in Black men is complex, requiring a patient-centered, community-centric and comprehensive approach. This study integrates iCCaRE Consortium findings and broader literature to address unmet needs in survivorship care. The iCCaRE Consortium implemented five complementary pilot studies using mixed-methods designs, including feasibility trials, qualitative research, and observational analyses across the United States and sub-Saharan Africa. Descriptive statistics, subgroup analyses, and qualitative thematic analyses were performed across these studies. Collectively, projects addressed multilevel determinants including social, behavioral, and biological drivers of disparities. Project 1 implemented a Virtual Reality Assistant (ViRA) across clinical and community settings, with ongoing evaluation in pragmatic trials. Project 2 showed strong patient preference for home-based cancer care. Project 3 enrolled demonstrated trends toward improved health-related quality of life. Project 4 identified key themes influencing survivorship experiences. Project 5 identified biological mechanisms linking stress, immune modulation, and symptom burden. The iCCaRE pilot projects demonstrate the feasibility and early impact of a consortium-based, transdisciplinary approach to addressing CaP disparities in Black men. These findings highlight the importance of integrating patient-centered interventions, community engagement, and biological insights to inform scalable strategies aimed at improving survivorship outcomes and advancing health equity. The iCCaRE Consortium demonstrates that a transatlantic, patient-centered, and multidisciplinary approach integrating social, clinical, and biological factors can generate scalable strategies to improve survivorship outcomes and advance equity in CaP care for Black men.
Elective genomic sequencing for adults in research, clinical and commercial contexts
Linderman, Michael D. , Adelson, Sophia , Berro, Tala , Crawford, Scott , Cunningham, Tshaka J., Esplin, Edward D. , Ewing-Crawford, Altovise T, Nielsen, Daiva E. , Andrighetti, Heather, Bleyl, Steven B., Haverfield, Eden , Hegde, Madhuri , Konstantinos, Lazaridis N, Leonard, Debra G. B. , May, Thomas , McGinniss, Molly, Pandya, Vaibhav, Schadt, Eric E. , Zettler, Bethany , Team, PeopleSeq Study, Adelson, Sophia M , Berro, Tala M , Crawford, Scott D , Esplin, Edward D , Nielsen, Daiva E , Pereira, Stacey , Schmidlen, Tara , Haverfield, Eden V , Hegde, Madhuri , Kruszka, Paul , Leonard, Debra , May, Thomas , Schadt, Eric E , Tzovaras, Bastian Greshake , Zettler, Bethany , McGuire, Amy L , Green, Robert C. , Berro, Tala M., Anderson, Jennifer L., Cunningham, Tshaka, Ewing, Altovise T. , Nielsen, Daiva E., Church, George M. , Konstantinos, Lazaridis N., McGinniss, Molly A. , Schadt, Eric E., Green, Robert C., Juusola, Jane , McWalter, Kirsty , Esplin, Ed, Haverfield, Eden, Hazell, Allison, Gu, Jessica, Hogan, Jennifer, Church, George , Ball, Mad Price , McGinnis, Molly, Schadt, Eric, Linderman, Michael, McGuire, Amy, Christensen, Kurt D. , Caskey, Thomas, Zoltick, Emilie S. , Crawford, Scott, Young, Robert, Hunsanger, Jillian, Bradley, Sophia, Cunningham, Tshaka, Roberts, Scott, Ricks‐Santi, Luisel , Lillard, James, Washington, Kareem N., Johnson, Anthony

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.09.26355296 | PMID 42369514 Get It

Abstract Purpose Elective genomic sequencing (EGS) returns monogenic disease findings in multiple genes, including potentially novel variants, and may also provide participants with carrier status, pharmacogenomic and other health-related information. The PeopleSeq Study assessed participants’ motivations for and concerns about EGS and the associated clinical and psychosocial outcomes across diverse EGS providers. Methods We administered a shared questionnaire to participants who chose to undergo EGS via 18 academic, clinical, or commercial EGS platforms. Results We enrolled 1575 participants, of whom 1147 (72.8%) completed a questionnaire after receiving their EGS results. A majority (60.3%) of the participants who completed a post-result questionnaire self-reported receiving results they assessed as important, including negative findings, and 75.9% reported a form of health-related utility. Among a subset (19.4%) who shared their EGS reports, 16.6% (37 of n =223) received a monogenic finding and self-reported results deemed “important” were consistent with EGS reports. Most participants (74.1%) discussed their results with their family, but fewer discussed their results with a healthcare provider other than the site team (41.7%) or had one or more medical visits as a direct result of their EGS testing (23.1%). Participants expressed diverse motivations for EGS, with 91.4% expressing interest in their personal disease risk and 54% who expressed quasi-indication-based motivations related to family medical history. Individuals motivated by family history reported important results at a significantly higher rate. Conclusions Early adopters of EGS are motivated by general interest in their health as well as quasi-indication-based considerations such as family history. A majority of participants learned results they considered medically important, but a much smaller segment engaged healthcare providers with their results.
Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States
Rawashdh, Neda Al, Patel, Bimal V. , Wang, Sharon M., Zur, Richard M., Anaya, Pablo, Pinsker, Jordan E., Sasson-Katchalski, Ravid, Trahan, Alex C., Assadi, Kimia, Kudva, Yogish C., Beck, Roy W., Al Rawashdh, Neda , Messer, Laurel H , Zur, Richard M. , Kahn, Emily B. , Pinsker, Jordan E. , Trahan, Alex C., Kudva, Yogish C. , Beck, Roy W.

Mayo Clinic

Diabetes, Obesity and Metabolism | May 6, 2026 | Volume: 28 | Issue: 7 | Pages: 6280-6290

10.1111/dom.70759 | PMID 42086278 Get It

ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE Diabetes Model v10.0 was employed to simulate the impact of using the t:slim X2 insulin pump with Control‐IQ+ technology (Control‐IQ+) versus MDI/CGM over a 50‐year period using data from the 2IQP randomized controlled trial (NCT05785832). Trial data informed cohort demographics, intervention effects and resource utilization while literature sources provided health state utilities and costs. Scenario analyses examined the effect of Control‐IQ+ on reducing HbA1c based on alternative HbA1c progression estimates from the Swedish National Diabetes Registry and alternative resource use and treatment effects from real‐world evidence. Results The base case analysis indicated that direct medical costs per individual for type 2 diabetes management with Control‐IQ+ were $239 935 compared to $209 792 with MDI/CGM use. Control‐IQ+ resulted in 0.51 additional quality‐adjusted life years (QALYs: 10.36 vs. 9.85 for MDI/CGM), yielding an incremental cost‐effectiveness ratio (ICER) of $59 417 per QALY, 95% CI: ($55 836, $62 998). In probabilistic sensitivity analyses, 89% of simulations produced ICERs below $100 000/QALY. ICERs across all scenarios remained below $100 000 per QALY. Conclusions Control‐IQ+ is associated with increased life expectancy, higher QALYs and reduced complication rates. These findings suggest that Control‐IQ+ is cost‐effective relative to MDI/CGM for managing patients with type 2 diabetes in the United States.
Guidelines for nutrition in adults with head and neck cancer: The American Society for Parenteral and Enteral Nutrition
Kiss, Nicole, Lewis, Whitney E, Mills, Jeannine B., Singh, Anurag K, Church, David D. , Mey, Jacob T. , Peterson, Sarah J. , Aguzzi, Kathleen, Bellini, Sarah Gunnell , Coelho, Maria Paula Villela, Cordwin, Laura, Duffy, Michael, Hager, Shanna J., Owen‐Michaane, Michael, Price, Kathleen C., Stanner, Heather , Storm, Bridget, Udagedara, Malika, McKeever, Liam , Church, David D , Mey, Jacob T , Peterson, Sarah , Bellini, Sarah , Coelho, Maria Paula Villela , Mundi, Manpreet S , Kiss, Nicole K. , Findlay, Merran , Frowen, Jacqui J. , Mundi, Manpreet S.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | March 8, 2026 | Volume: 50 | Issue: 3 | Pages: 274-338

10.1002/jpen.70067 | PMID 41773753 Get It

Abstract Background Head and neck cancer represents the seventh most common cancer diagnosis globally. Maintaining sufficient nutrition is important for preventing malnutrition (undernutrition) and muscle wasting, which contribute to worse outcomes, although many patients are unable to maintain adequate oral intake throughout treatment. This guideline provides practice guidance on nutrition care for patients with head and neck cancer. Methods An interdisciplinary team developed key questions and scanned results from a systematic search of the PubMed, EMBASE, CINAHL, and Cochrane Central databases back to 2001. Recommendations were created for key questions concerning timing and duration of nutrition support (early vs delayed enteral nutrition [EN], postoperative feeding, and perioperative dietitian intervention), frequency of dietitian and speech pathology consultations, nutrition screening and assessment, macronutrient requirements, enteral access devices, adjunctive strategies (appetite stimulants and continuation of oral intake alongside EN), specialized nutrients (arginine, glutamine, ω‐3, and immunonutrition), and interdisciplinary care. Results Ninety‐two studies were included. Recommendations were made supporting early initiation of EN when oral intake is inadequate, nutrition within 24 h after surgery, weekly consultation with a dietitian during radiotherapy, malnutrition screening and assessment with validated tools, interdisciplinary models of care, dietitian involvement before and after surgery, and when to consider use of specialized nutrients. Recommendations are also provided for protein intake (1.2–1.5 g/kg/day) and energy intake (≥30 kcal/kg/day). Conclusion This guideline provides guidance for the nutrition care of patients with head and neck cancer, identifies research gaps, and calls for standardized outcome reporting to further the state of the evidence. This paper was approved by the ASPEN Board of Directors.
Community-based participatory design of a decade: the FAITH! Cardiovascular Health and Wellness Program
Lalika, Mathias , Kyalwazi, Ashley, Albertie, Monica, Bowie, Janice , Burgess, Ashya, Elegbede, Walé, Erickson, Jamia, Jenkins, Sarah M. , Johnson, Jacquelyn, Krogman, Ashton , Moen, Lainey , Palmer, Michael W. , Penheiter, Sumedha G., Richard, Monisha, Titus, Princess, Schardin, Sueling, Shanedling, Stanton , Hof, Jeremy Van’t , Weis, Jennifer A., Patten, Christi A. , Penheiter, Sumedha, Warner, David, Weis, Jennifer, Brewer, LaPrincess C. , Burke, Lora E. , Buta, Brian J. , Cooper, Lisa A. , Crews, Deidra C. , Doubeni, Chyke A. , Johnson, Jacquelyn, Jones, Clarence , Palmer, Michael, Warner, David O. , Hayes, Sharonne N.

Mayo Clinic

Frontiers in Public Health | September 23, 2025 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fpubh.2025.1622237 | PMID 41063935 Get It

The FAITH! (Fostering African-American Improvement in Total Health) Cardiovascular Health and Wellness Program is more than a decade-long community-based participatory research initiative aimed at addressing cardiovascular health disparities among African-Americans in Minnesota. Founded in 2013, the program employs a culturally tailored, community-driven approach by partnering with African-American faith communities to promote cardiovascular health through education, digital health tools, and multilevel interventions targeting the social determinants of health. Grounded in community-based participatory research principles, FAITH! prioritizes equitable academic-community partnerships, co-learning, community capacity building, and shared ownership in all aspects of research and implementation. The program’s exemplary innovations include the NIH-funded FAITH! Trial, a randomized clinical trial, testing a mobile health intervention (the FAITH! App) co-created with the African-American community, and the Techquity by FAITH! study. Techquity by FAITH! evaluates the effectiveness of a culturally relevant, community-informed mHealth intervention supported by a Digital Health Advocate network to improve overall cardiovascular health and digital health literacy. During its evolution, FAITH! has addressed emergent public health crises, including the COVID-19 pandemic, by adapting programming to provide emergency preparedness resources, health education, and vaccine outreach. Key outcomes include sustainable church-based health ministries, increased research participation, and successful translation of research into practice. The program has also contributed to research workforce development by mentoring and training diverse early-career scholars and community leaders in community-based participatory research and cardiovascular health equity research. Lessons learned highlight the transformative impact of community-based participatory research in building trust, facilitating culturally relevant dissemination, and sustaining health equity initiatives. The FAITH! model demonstrates a scalable, community-led strategy for advancing cardiovascular health in underserved populations and provides a blueprint for future initiatives aiming to reduce racial health disparities.
Abstract A024: Whole person survivorship: Multilevel distress in prostate cancer survivors from priority communities
Willis, Floyd B. , Song, Gaole , Bedell, Fornati, Moore, Cassandra N., Cobran, Ewan K. , Bonner, Timethia , Dagne, Getachew , Merriweather, Arnold, Kaninjing, Ernie, Oladapo, Rotimi, Dronca, Roxana , Dottington, Fullwood, Odedina, Folakemi T., Ashing, Kimlin , Williams, Christopher Michael , McCall, John , Ngufor, Che

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 18, 2025 | Volume: 34 | Issue: 9_Supplement | Pages: A024-A024

10.1158/1538-7755.disp25-a024 Get It

Abstract Introduction: Advances in treatment have led to significant increases in survival rates, with over 90% of men diagnosed with prostate cancer (CaP) living at least five years. However, surviving cancer and its treatment often weigh a hefty survivorship burden. Men from the at-risk, vulnerable populations have the greatest burden. This study aims to understand distress among Black CaP survivors (CaPS) who bear the heaviest CaP burden. Method: We conducted key informant interviews with Motivational Interviewing techniques to collect CaPS demographic information, medical history, and multilevel distress evaluation. Descriptive analyses were conducted using SAS. Results: A total of 22 CaPS (aged from 48 to 72) were involved in the study. The majority of CaPS were African American (90.9%) and were diagnosed with stage 2 (31.8%) or stage 3 (36.4%). Over half of them (68.2%) were treated by surgery; most CaPS (90.9%) experienced side effects from prostate cancer treatments. CaPS reported distress in the following domains: Emotional well-being (e.g., Feeling sad, depressed or anxious, mental health) – 40.9%, Death of someone very close to you (e.g., family) – 36.4%, Alcohol use in close family – 36.4%, Experiences of discrimination or racism – 36.4%, Healthcare costs and coverage (e.g., medication, medical services, copay, insurance premium) – 31.8%, Loneliness and isolation – 27.3%, Serious injury/illness in close family (e.g., being a caregiver) – 27.3%, Money and finance – 22.7%, Using telehealth (e.g., using a smartphone or tablet for telephone or over the computer, clinic visit, patient portal, completing online forms, virtual classes) – 22.7%, Marriage, romantic relationships – 22.7%. Discussion: Black CaP survivors (CaPS) who bear the heaviest CaP burden are considered a priority population for research and care. These CaPS identified that their psychological distress was related to both familial and socioeconomic issues. The most endorsed life-stresses included emotional wellbeing, experiences of discrimination/racism, loneliness and isolation, healthcare cost/finance, family health, personal relationship, and telehealth use. The distress data as measured by the life-stress scale are invaluable in better documenting and addressing distress in interventions responsive to specific priority communities. Our novel findings suggest the relevance of grief and loss for these men. 36% reported death of someone close, and 27% indicated distress due to loneliness and isolation. Though the sample size was small, the distress data obtained may inform the science and practice of whole-person survivorship that consider distress emphasizing emotional wellbeing. The study is ongoing, and this abstract presents preliminary results; further muti-variate analyses will be conducted for the conference presentation. Citation Format: Kimlin Ashing, Floyd Willis, Chris Williams, John Mccall, Gaole Song, Fornati Bedell, Cassandra Moore, Ewan Cobran, Che Ngufor, Timethia Bonner, Getachew Dagne, Arnold Merriweather, Ernie Kaninjing, Rotimi Oladapo, Roxana Dronca, Fullwood Dottington, Folakemi Odedina. Whole person survivorship: Multilevel distress in prostate cancer survivors from priority communities [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr A024.
Challenges in the return of molecular tumor profiling results
Lenz, Heinz-Josef, Craig, David W. , Johnson, Kevin C. , Verhaak, Roel G.W. , Bhattacharyya, Oindrila , Davis, Bethany , Wesley, C. John, Byron, Sara A. , Willman, Cheryl L. , Kelley, Lindsey , Claus, Elizabeth B. , Trent, Jeffrey M. , Culver, Julie O. , Church, Alanna J. , Lenz, Heinz-Josef , Verhaak, Roel Gw , Willman, Cheryl , Trent, Jeffrey M , Gray, Stacy W , Church, Alanna J , Wesley, Cherie, Kelley, Lindsey , Claus, Elizabeth B , Gray, Stacy W.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 5, 2025 | Volume: 118 | Issue: 5 | Pages: 776-782

10.1093/jnci/djaf251 | PMID 40929086 Get It

Abstract Next-generation sequencing has transformed cancer care by providing essential insights for diagnosis, prognosis, and treatment. However, variability in testing timing, reporting practices, and interpretation challenges limits its clinical impact. This article highlights key opportunities to optimize somatic reporting, emphasizing the importance of timely testing throughout the cancer care continuum to maximize the diagnostic and therapeutic relevance of findings. Technical factors such as test design, sequencing depth, and the use of liquid biopsy substantially influence result accuracy and interpretation, underscoring the need for careful integration with clinical history. Standardized reporting practices that clearly delineate diagnostic, prognostic, and therapeutic findings can enhance the clinical utility of next-generation sequencing results. Streamlined formats and curated clinical trial data further support actionable decision making. Additionally, direct patient engagement and education are essential for empowering patients to navigate genomic testing and make informed decisions about their care. By leveraging multidisciplinary tumor boards, decision-support tools, and emerging artificial intelligence technologies, clinicians can better navigate the complexities of somatic reports. Standardization and clarity in reporting are critical to advancing precision oncology, empowering providers and patients to make informed treatment decisions and improve outcomes.
E-059 Influence of race on extended length of stay following mechanical thrombectomy for anterior circulation stroke
Koo, A, Johnson, Scott, Starke, R, Welch, Babu G. , Rivet, Dennis J. , Graffeo, Christopher S. , Klopfenstein, Jeffrey D., Sahlein, D, Eshraghi, Sheila, Altschul, D, Alaraj, A, Davies, Jason M., Raper, D, Park, M , Malek, Adel M. , Monteith, Stephen J., Eckardt, Glenn S., Beaty, N, Schirmer, C, Arthur, A, Wolfe, S, Chen, C, Church, E, Dornbos, D, Chu, T, Johnson, S, Starke, R, Altschul, David , Ringer, Andrew J. , Hoh, Brian L. , Alaraj, Ali , Mocco, J , Grande, Andrew Walker , Eckardt, G, Beaty, Narlin Bennet , Schirmer, Clemens M., Arthur, A, Dornbos, David

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A132.1-A132

10.1136/jnis-2025-snis.175 Get It